Engene Holdings [ENGNW] vs Vertex [VRTX] Detailed Stock Comparison

Engene Holdings Inc.

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Engene Holdings Inc. wins in 4 metrics, Vertex Pharmaceuticals Inc. wins in 7 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Engene Holdings Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) N/A 28.40 N/A
Price-to-Book Ratio 0.55 5.92 Engene Holdings Inc.
Debt-to-Equity Ratio 11.89 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio N/A 0.88 N/A
EV/EBITDA 0.16 21.78 Engene Holdings Inc.
Profit Margin (TTM) 0.00% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) 0.00% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -46.07% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -25.63% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-100.72M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 284.48% -2.31% Engene Holdings Inc.
Price-to-Sales Ratio (TTM) N/A 9.22 N/A
Enterprise Value $-18.36M $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio N/A 8.83 N/A
Gross Profit Margin (TTM) N/A 85.39% N/A
Revenue per Share (TTM) N/A $47 N/A
Earnings per Share (Diluted) N/A $15.32 N/A
Beta (Stock Volatility) -0.05 0.37 Engene Holdings Inc.
Short % of Float N/A 1.78% N/A

Engene Holdings Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

ENGNW
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Engene Holdings Inc.-88.33%-88.34%-88.34%-88.34%-90.08%-91.03%
Vertex Pharmaceuticals Inc.1.24%1.69%3.09%-3.36%-1.15%-0.37%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Engene Holdings Inc.284.48%123.00%123.00%123.00%123.00%123.00%
Vertex Pharmaceuticals Inc.-2.31%27.89%136.85%413.01%888.51%1,245.83%

Performance & Financial Health Analysis: Engene Holdings Inc. vs Vertex Pharmaceuticals Inc.

MetricENGNWVRTX
Market Information
Market Cap i$0$109.45B
Market Cap CategoryMicro capLarge cap
10 Day Avg. Volume i9,3621,057,061
90 Day Avg. Volume i4,0971,272,097
Last Close$0.26$450.46
52 Week Range$0.26 - $4.20$362.50 - $507.92
% from 52W High-93.80%-11.31%
All-Time High$6.38 (Mar 18, 2024)$519.88 (Nov 04, 2024)
% from All-Time High-95.92%-13.35%
Growth Metrics
Quarterly Revenue GrowthN/A0.10%
Quarterly Earnings GrowthN/A0.31%
Financial Health
Profit Margin (TTM) i0.00%0.33%
Operating Margin (TTM) i0.00%0.40%
Return on Equity (TTM) i-0.46%0.23%
Debt to Equity (MRQ) i11.8910.91
Cash & Liquidity
Book Value per Share (MRQ)$4.20$73.49
Cash per Share (MRQ)$4.12$26.01
Operating Cash Flow (TTM) i$-102,446,000$3.63B
Levered Free Cash Flow (TTM) i$-65,304,376$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Engene Holdings Inc. vs Vertex Pharmaceuticals Inc.

MetricENGNW (Apr 23, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A28.40
Forward P/E iN/A19.95
PEG Ratio iN/A0.88
Price to Sales (TTM) iN/A9.22
Price to Book (MRQ) i0.555.92
Market Capitalization
Market Capitalization i$0$109.45B
Enterprise Value i$-18,357,000$105.96B
Enterprise Value Metrics
Enterprise to Revenue iN/A8.83
Enterprise to EBITDA i0.1621.78
Risk & Other Metrics
Beta i-0.050.37
Book Value per Share (MRQ) i$4.20$73.49

Financial Statements Comparison: Engene Holdings Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricENGNW (2025)VRTX (2025)
Revenue/Sales i012.00B
Cost of Goods Sold iN/A1.65B
COGS % of Revenue i-13.8%
Gross Profit iN/A10.35B
Gross Margin i-86.2%
Research & Development i94.48M4.04B
Operating Income (EBIT) i-123.17M4.55B
Operating Margin i-37.9%
EBITDA i-113.80M5.25B
EBITDA Margin i-43.7%
Pre-Tax Income i-117.30M4.64B
Pre-Tax Income % of Revenue i-38.7%
Income Tax i0690.00M
Income Tax % of Revenue i-5.7%
Net Income (Profit) i-117.30M3.95B
Profit Margin i-32.9%

Balance Sheet & Liquidity Metrics

MetricENGNW (2025)VRTX (2025)
Cash & Equivalents i50.15M5.08B
Total Current Assets i201.39M11.20B
Total Current Assets % of Revenue i-93.3%
Total Current Liabilities i31.98M3.86B
Total Current Liabilities % of Revenue i-32.2%
Long-Term Debt i21.78M1.95B
Long-Term Debt % of Revenue i-16.3%
Total Shareholders Equity i167.71M18.67B
Retained Earnings i-372.03M13.56B
Retained Earnings % of Revenue i-113.0%
Property, Plant & Equipment i3.13M1.56B

Cash Flow Statement Comparison

MetricENGNW (2025)VRTX (2025)
Operating Cash Flow i-101.29M3.77B
Operating Cash Flow % of Revenue i-31.4%
Capital Expenditures i-1.49M-437.60M
Free Cash Flow i-100.72M3.19B
FCF Margin i-26.6%
Debt Repayment i-699,000-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricENGNWVRTX
Shares Short iN/A4.02M
Short Ratio iN/A2.80
Short % of Float iN/A1.78%
Shares Outstanding i66.99M253.99M
Float Shares i26.44M253.24M
% Held by Insiders iN/A0.21%
% Held by Institutions iN/A97.60%
% Held by Public iN/A2.19%

Dividend Analysis & Yield Comparison: Engene Holdings Inc. vs Vertex Pharmaceuticals Inc.

MetricENGNWVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A